3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma
6
Leukemia, Lymphocytic, Chronic, B-Cell
4
Recurrence
3
Lymphoma, Follicular
3
Leukemia
2
Stomach Neoplasms
1
Neoplasms
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, B-Cell
1
Interventions
Exercise
19
Drug Therapy
18
pembrolizumab
13
Capecitabine
11
Blood Specimen Collection
11
Surveys and Questionnaires
10
Radiotherapy
10
Paclitaxel
9
Dexamethasone
9
Nivolumab
8
Standard of Care
7
Oxaliplatin
7
Fluorouracil
7
Erlotinib Hydrochloride
7
apatinib
6
Interviews as Topic
6
Gemcitabine
6
Control Groups
6
Cisplatin
6
Therapeutics
5
Neoadjuvant Therapy
5
Mindfulness-Based Cognitive Therapy
5
Metformin
5
Injections
5
Everolimus
5
Docetaxel
5
Cyclophosphamide
5
Bevacizumab
5
sintilimab
4
atezolizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Neoplasms
×
Chlorambucil
×
Clear all
NCT01657955
2012-08-06
CLL
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase 3
Unknown
96 enrolled